(Q71015295)

English

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease

scientific article published on 01 February 1996

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8607241%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8607241%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Zietman AL

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8607241%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

Dallow KC

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8607241%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

McManus PA

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8607241%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

Heney NM

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8607241%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

Shipley WU

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8607241%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

language of work or name

0 references

publication date

1 February 1996

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8607241%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8607241%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

47

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8607241%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8607241%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

236-239

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8607241%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

Randomized Trials in Loco-Regionally Confined Prostate Cancer: Past, Present, and Future

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980423-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended field (periaortic) irradiation in carcinoma of the prostate--analysis of RTOG 75-06

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980423-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: preliminary results of RTOG 83-07

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980423-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980423-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Surrogate markers in AIDS and cancer trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980423-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980423-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostatic-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980423-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(99)80423-3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8607241%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8607241%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q71015295&oldid=1942517698"